J. McCarville

发表

Ku Recruits the XRCC4-Ligase IV Complex to DNA Ends

D. Ramsden, S. A. Nick McElhinny, Carey M Snowden, 2000, Molecular and Cellular Biology.

In vitro Activity and Resistance Profile of Samatasvir , a Novel NS 5 A Replication Inhibitor 1 of Hepatitis C Virus 2

J. Bilello, J. McCarville, L. Lallos, 2014 .

In Vitro Activity and Resistance Profile of Samatasvir, a Novel NS5A Replication Inhibitor of Hepatitis C Virus

J. Bilello, J. McCarville, L. Lallos, 2014, Antimicrobial Agents and Chemotherapy.

High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma

R. Dahiya, G. Deng, J. McCarville, 1997, International journal of cancer.

The CUL1 C-Terminal Sequence and ROC1 Are Required for Efficient Nuclear Accumulation, NEDD8 Modification, and Ubiquitin Ligase Activity of CUL1

Y. Xiong, T. Ohta, Yanping Zhang, 2000, Molecular and Cellular Biology.

Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using Escherichia coli lysate.

Michael D. Miller, Xiaohong Liu, H. Mo, 2015, Journal of virological methods.

A Role for Saccharomyces cerevisiae Cul8 Ubiquitin Ligase in Proper Anaphase Progression*

Yue Xiong, Y. Xiong, J. McCarville, 2003, Journal of Biological Chemistry.

Rapid Decline of Viral RNA in Chronic Hepatitis C Patients Treated Once Daily with IDX320: A Novel Macrocyclic HCV Protease Inhibitor

K. Simon, C. Weegink, H. Reesink, 2012, Antiviral therapy.

Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection

D. Asmuth, H. Vargas, J. McCarville, 2012, Antimicrobial Agents and Chemotherapy.

In Vitro Activity and Resistance Proﬁle of Samatasvir, a Novel NS5A Replication Inhibitor of Hepatitis C Virus

J. Bilello, J. McCarville, L. Lallos, 2014 .

Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor.

Catherine Caillet, J. McCarville, M. Liuzzi, 2017, Bioorganic & medicinal chemistry letters.

Synthesis of 2'-O,4'-C-alkylene-bridged ribonucleosides and their evaluation as inhibitors of HCV NS5B polymerase.

J. McCarville, I. Serra, C. Chapron, 2014, Bioorganic & medicinal chemistry letters.

588 IN VITRO ANTIVIRAL ACTIVITY AND PHARMACOLOGY OF IDX184, A NOVEL AND POTENT INHIBITOR OF HCV REPLICATION

L. Licklider, J. Bilello, J. McCarville, 2008 .

Idx184 in Combination with Pegylated Interferon-α2A and Ribavirin for 2 Weeks in Treatment-Naive Patients with Chronic Hepatitis C

P. Kwo, W. O'Riordan, J. McCarville, 2013, Antiviral therapy.

Deletion of chromosome 11p15, p12, q22, q23‐24 loci in human prostate cancer

R. Dahiya, G. Deng, J. McCarville, 1997, International journal of cancer.

Chromosome 3p24‐26 and 3p22‐12 loss in human prostatic adenocarcinoma

R. Dahiya, G. Deng, J. McCarville, 1997, International journal of cancer.

Evidence that the Human Cytomegalovirus IE2-86 Protein Binds mdm2 and Facilitates mdm2 Degradation

J. Dantonel, Zhigang Zhang, S. Huong, 2006, Journal of Virology.

Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.

J. McCarville, M. Liuzzi, Cyril Dousson, 2016, Bioorganic & medicinal chemistry letters.

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.

L. Webster, W. O'Riordan, E. Lawitz, 2014, Journal of hepatology.

1209 TREATMENT-EMERGENT VARIANTS FOLLOWING 3 DAYS OF MONOTHERAPY WITH IDX719, A POTENT, PAN-GENOTYPIC NS5A INHIBITOR, IN SUBJECTS INFECTED WITH HCV GENOTYPES 1–4

J. McCarville, D. Mayers, M. Seifer, 2013 .

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.

L. Webster, W. O'Riordan, E. Lawitz, 2014, Journal of hepatology.